FDA Approves AstraZeneca COPD Medicine

Published on: 

Pharmaceutical Executive

AstraZeneca announced that the FDA has approved its SYMBICORT (budesonide/formoterol fumarate dihydrate) inhalation aerosol 160/4.5 micrograms to decrease exacerbations of chronic obstructive pulmonary disease (COPD).

SYMBICORT 160/4.5 works to maintain treatment of airflow obstruction in patients with COPD-including chronic bronchitis and/or emphysema-and to lessen COPD exacerbations.

SYMBICORT has not been indicated for the relief of acute bronchospasm.


For mor information, read the prescribing information, boxed warning, and medication guide here.